River blindness: A success story under threat? by Basanez, M-G et al.
PLoS Medicine  |  www.plosmedicine.org 1454
Neglected Diseases
September 2006  |  Volume 3  |  Issue 9  |  e371
“The accomplishments of this Programme inspire all of us in public health to dream big dreams. It shows we can reach ‘impossible’ goals and lighten 
the burden of millions of the world’s poorest people ... .” 
These were the concluding words by former World Health 
Organization Director-General Gro Harlem Brundtland 
at the closure ceremony of the Onchocerciasis Control 
Programme in West Africa (OCP) in December 2002 [1]. 
The success of the OCP is so undeniable and exemplary, 
with 600,000 cases of blindness prevented, 18 million 
children born in areas freed from the risk of blindness, and 
25 million hectares of land safe for resettlement, that river 
blindness is currently considered a disease of the past. This 
perception nonetheless forgets that OCP covered, at most, 
1,200,000 square kilometers to protect 30 million people in 
11 countries, leaving a remaining 100 million people in areas 
where active transmission of onchocerciasis still occurs. After 
its 28-year ﬁ ght OCP may have won a battle, but a much more 
difﬁ cult task lies ahead before we can claim victory against 
river blindness [2]. 
Etiology and Distribution
Human onchocerciasis is caused by the ﬁ larial parasitic 
nematode Onchocerca volvulus. Adult worms (macroﬁ lariae) 
live in subcutaneous nodules and deeper worm bundles, 
where fertilized females can produce, during an average of 10 
years, millions of microﬁ lariae responsible for the morbidity 
associated with the infection. Ingested during a bloodmeal 
by Simulium (black ﬂ y) vectors, microﬁ lariae develop within 
the ﬂ y to infective (L3) stages, that are then transmissible to 
other people (Figure 1). Many simuliid species have been 
incriminated to a greater or lesser degree in the transmission 
of O. volvulus [3], their relative vectorial roles contributing 
to shape diverse transmission patterns across endemic areas. 
In Africa, the Simulium damnosum sensu lato (s.l.) species 
complex, which includes approximately 60 cytoforms, is 
responsible for more than 95 percent of onchocerciasis cases 
globally [3,4]. In Latin America, S. ochraceum s.l., S. exiguum 
s.l., S. metallicum s.l., and S. guianense s.l. are the main vectors, 
respectively, in Mexico and Guatemala (about 360,000 people 
at risk), Colombia and Ecuador (24,600), northern Venezuela 
(104,500), and southern Venezuela and Brazil (20,000) [5,6]. 
O. volvulus is endemic in 27 sub-Saharan African countries, 
the Yemen [7], and was imported through the slave trade 
to six Latin American countries. Previous estimates have 
placed the number of people infected worldwide at 18 
million [7], 99 percent of them in Africa. Since then, the true 
extent of the disease has been estimated by REMO (rapid 
epidemiological mapping of onchocerciasis). Villages are 
selected in each river basin according to appropriate criteria, 
and levels of endemicity are assessed by onchocercal nodule 
prevalence in adult host samples [8]. By 2005, more than 
22,000 villages in Africa (outside the OCP area) had been 
surveyed, allowing the identiﬁ cation of many new foci (Figure 
2). The new infected populations thus found, together 
with their demographic increase, certainly compensate for 
the number of cases prevented by the OCP (where it was 
estimated that roughly 3 million people were infected [7]). 
Presently, it is estimated that 37 million people carry 
O. volvulus, with 90 million at risk in Africa [9]. 
Clinical Manifestations and Pathogenesis
Onchocerciasis is better known as river blindness because 
of the high prevalence of blindness in villages located along 
fast-ﬂ owing rivers, where the vectors breed. Up to 500,000 
cases of severe visual impairment (including visual ﬁ eld 
reduction), and 270,000 of blindness have been attributed 
to onchocerciasis [7], but, again, these ﬁ gures certainly 
underestimate the true magnitude of the problem. Ocular 
lesions can involve all eye tissues, ranging from punctate 
and sclerosing keratitis (anterior segment) to optic nerve 
atrophy (posterior segment). Blindness incidence has 
recently been shown to be associated with past microﬁ larial 
load in individuals followed up within the OCP cohort [10], 
conﬁ rming the progressive worsening of onchocercal eye 
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disease with parasite exposure (Figure 3A). Conventionally, 
anterior chamber lesions had been attributed to a cascade of 
inﬂ ammatory processes triggered by ﬁ larial products [11]. A 
novel hypothesis proposes that the pro-inﬂ ammatory events 
leading to increasing corneal opacity are stimulated not 
only by the parasite itself, but also by its recently discovered 
endosymbiotic Wolbachia bacteria, when released by dying 
microﬁ lariae [12,13]. By contrast, the pathogenesis of 
retinal lesions, which may continue progressing despite 
parasite clearance after chemotherapy, may result from 
autoimmune processes elicited by cross-reactivity between 
the O. volvulus antigen Ov39 and the human retinal antigen 
hr44 [14]. 
Onchocerciasis also causes troublesome itching and 
skin changes ranging from early, reactive lesions—acute 
papular onchodermatitis, chronic papular onchodermatitis, 
and licheniﬁ ed onchodermatitis—to late changes such as 
depigmentation and skin atrophy [15]. When limited to 
DOI: 10.1371/journal.pmed.0030371.g001
Figure 1. Life Cycle of O. volvulus
Mean dimensions of parasite stages are: Adult females, 35-70 cm × 400 µm; adult males, 2-4 cm × 150-200 µm; microﬁ lariae, 250-360 × 5-9 µm; L1 
larvae, 200 µm × 12 µm (front) and 20 µm (rear); L3, 440-700 × 20 µm. L1 larvae molt into L2, pre-infective larvae, and L2 into L3, infective larvae [5].
(Illustration: Giovanni Maki, derived from a CDC image at http://www.dpd.cdc.gov/dpdx/HTML/Filariasis.htm)
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one limb, licheniﬁ ed onchodermatitis is also called “sowda.” 
Despite high skin microﬁ larial loads in endemic areas, most 
patients present with subclinical or intermittent dermatitis 
corresponding to acute papular onchodermatitis, with 
little cellular attack against live microﬁ lariae (generalized 
onchocerciasis). Clinical lesions correspond to inﬁ ltrates 
around dead or degenerating microﬁ lariae surrounded 
by macrophages, eosinophils, and neutrophils [16]. As in 
the cornea, inﬂ ammation appears to be largely induced 
by Wolbachia endobacterial products [13]. In generalized 
onchocerciasis, the T helper cell type 1– and T helper cell 
type 2–dependent effector reactions are suppressed by a 
third arm of the T helper pathway, the T helper cell type 3, 
or T regulatory cell type 1 [17]. Antigen-speciﬁ c T regulatory 
cell type 1 cells constitute a major source of interleukin 10, 
leading to a downregulation of the immune system that 
both prevents immune-mediated damage and facilitates 
parasite survival [13]. By contrast, patients with severe or 
hyperreactive skin lesions, such as licheniﬁ ed onchodermatitis 
or sowda, often present with low microﬁ larial loads. Their 
lesions are due to repeated cycles of inﬂ ammation, eosinophil 
and macrophage inﬁ ltration, and destruction of live and dead 
microﬁ lariae [18]. These different immune responses to the 
parasite and ensuing clinical presentation may be inﬂ uenced 
by host genetic factors [19]. 
Onchocerciasis is also a systemic disease that is associated 
with musculoskeletal pain, reduced body mass index, and 
decreased work productivity. This may be due to the fact 
that microﬁ lariae can invade many tissues and organs, 
and be found in blood and urine [5]. Involvement of 
heavy microﬁ larial infection is also suspected in the onset 
of epilepsy [20] and the hyposexual dwarﬁ sm known as 
Nakalanga syndrome [21]. A direct association between 
microﬁ larial load and excess mortality of the human host has 
been demonstrated recently [22] (Figure 3B). 
Epidemiological Patterns
In contrast with some soil-transmitted helminths and 
schistosomes, whose worm burdens typically peak in the 
young, age-speciﬁ c patterns of O. volvulus infection show 
strong variation according to locality (microﬁ larial loads 
can increase, decrease, or plateau with age), and may differ 
markedly with host sex. Age- and sex-speciﬁ c exposure, 
endocrine factors, and parasite-induced immunosuppression 
have been forwarded as possible explanations [23,24]. These 
patterns have implications for O. volvulus population biology 
and the design of control strategies. 
The rationale behind the establishment of the OCP in 
savannah areas of 11 West African countries was based on 
the observation that there was a blinding savannah parasite 
strain, transmitted by savannah members of S. damnosum 
s.l., and a non-blinding forest strain, transmitted by forest 
members. Cross-experimental infections had indicated 
strong local adaptation and heterologous incompatibility, 
suggesting that the existence of O. volvulus–S. damnosum 
complexes could be responsible for the distinct distribution 
and severity of onchocercal blindness [25]. DNA-based 
methods conﬁ rmed an association between savannah and 
forest parasite types with, respectively, severe and mild ocular 
onchocerciasis [26]. In West African savannah, blindness 
prevalence correlates positively with intensity of infection in 
the community, a relationship rarely observed in West African 
forest [27]. The geographic distribution of severe and mild 
visual impairment is not, however, neatly conﬁ ned to the 
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Figure 2. Distribution of Onchocerciasis Showing Current Status of Global Onchocerciasis Control 
Red areas represent areas receiving ivermectin treatment. Yellow areas represent areas requiring further epidemiological surveys. The green area is 
the area covered by the Onchocerciasis Control Programme in West Africa. Pink zones indicate the special intervention zones, i.e., previous OCP areas 
receiving ivermectin and some vector control. Map redrawn from [53,75,76].
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savannah/forest divide. There are forest and forest–savannah 
mosaic areas with high blindness prevalence [28] and 
parasites distinct from those in West Africa, while in others, 
parasites genetically indistinguishable from West African 
savannah isolates are not associated with blindness [29,30]. 
The pathogenic differences of the various strains may be a 
function of their relative Wolbachia load [31]. 
Disease Burden and Socioeconomic Consequences
The true burden of onchocerciasis has largely been 
underestimated. Excess mortality of the blind, particularly 
among males, may be considerable [32,33]. Even in 
sighted individuals, high microﬁ larial load can negatively 
affect a host’s life expectancy [22]. Parasite-induced 
immunosuppression to speciﬁ c and non-speciﬁ c antigens 
[34], impairment of the ability to fend off infections and 
seroconvert successfully upon vaccinations [35], and 
manifestations such as epilepsy possibly due to heavy infection 
[20] may be partially responsible for excess mortality. It 
is also well known that onchodermatitis and epilepsy are 
associated with social stigmatization [36]. Onchocerciasis 
is deemed responsible for the annual loss of approximately 
1 million disability-adjusted life-years—healthy life-years 
lost due to disability and mortality (more than half of 
them due to skin disease [37])—which greatly reduces 
income-generating capacity [38], incurs signiﬁ cant health 
expenditures, and exerts, overall, an immensely negative 
socioeconomic impact on the afﬂ icted populations and their 
land use [39]. Although not the only cause of depopulation 
in some otherwise fertile West African valleys, onchocerciasis 
prevented resettlement of these arable lands [40]. The 
beneﬁ ts accrued through onchocerciasis control programs 
should be measured not only in terms of blindness cases 
prevented and the cost-effectiveness of treatment [41,42], but 
also in terms of number of deaths averted. 
Onchocerciasis Control Strategies
The mainstay of onchocerciasis control is through 
antivectorial and antiparasitic measures. The former 
are directed against the black ﬂ y aquatic stages, and the 
latter against the microﬁ lariae. As yet there is no effective 
macroﬁ laricidal drug that is safe for mass treatment. The OCP 
initially implemented weekly larviciding of vector breeding 
grounds, with the aim of interrupting transmission in the core 
OCP area. After achieving this, elimination of the parasite 
required abolishing vector sources for as long as microﬁ lariae 
remain in human skin. This duration was deemed to be 
at least 14 years (considering the life expectancies of both 
adult worms and microﬁ lariae) [43]. In some parts of the 
OCP area, children born after the initiation of vector control 
proved to be uninfected [44]. In 1987, Merck took the 
unprecedented decision to donate ivermectin (Mectizan), 
an effective and safe microﬁ laricide, for as long as necessary 
to eliminate onchocerciasis as a public health problem. 
Following this commitment, regular ivermectin distribution by 
mobile teams was introduced to complement vector control 
in some OCP areas, or as the sole intervention in others [45]. 
Ivermectin, given at the dose of 150 micrograms per kilogram 
of body weight, acts as a highly effective microﬁ laricide and 
inhibits microﬁ larial production by female worms for several 
months. Mass administration of ivermectin (to all those aged 
ﬁ ve years or older, excluding pregnant women and those 
breastfeeding a child younger than one week old) once or 
twice per year reduces morbidity and disability [46,47] and 
lowers transmission [48,49]. Given the high initial endemicity 
in some foci, annual regimes are not considered sufﬁ cient to 
achieve local elimination of parasite populations [50], unless 
very high therapeutic coverage (more than 80 percent of the 
total population) is achieved for at least 25 years without loss 
of treatment efﬁ cacy [51]. 
In Latin America, focal vector control was conducted in 
Guatemala with some degree of success against the local 
S. ochraceum s.l. vector [52], but was otherwise considered 
impractical. The Onchocerciasis Elimination Program for 
the Americas (OEPA) was initiated in 1993 as a regional 
partnership to eliminate all morbidity from onchocerciasis 
(and suppress its transmission wherever possible) in foci 
of the six affected Latin American countries [53]. OEPA’s 
strategy is currently based on biannual mass ivermectin 
distribution, as it was considered that treatment every six 
months would have a greater impact on transmission [54] 
and female worm fecundity [55]. 
In 1995, the African Programme for Onchocerciasis 
Control (APOC) was launched in order to cover the 
remaining 19 African countries not protected under the 
OCP umbrella [56]. (Three of them, Kenya, Rwanda, and 
Mozambique, were found not to be endemic.) Since then, 
APOC’s strategy has been based on annual ivermectin 
distribution. The levels of geographic (percentage of 
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Figure 3. The Incidence of Blindness and Excess Mortality Rate, by 
Sex, Plotted against O. volvulus Microﬁ larial Load 
Arithmetic mean of microﬁ larial counts from two skin snips, taken from 
the right and left ileac crests, using a 2-millimeter Holth corneoscleral 
punch. (A) Blindness; (B) excess mortality rate. Error bars denote 95 
percent conﬁ dence intervals [10,22].
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villages treated in an area) and therapeutic (percentage of 
population treated in a village) coverage achieved by mobile 
teams tended to be unsatisfactory, with little prospects of 
sustainability. Instead, APOC has implemented, with great 
success, the modality of community-directed treatment 
with ivermectin (CDTI), by which communities themselves 
appoint accountable local distributors [57]. By the end 
of 2005, 400 million treatments had been supplied by the 
Mectizan Donation Program, with an estimated 40 million 
people living in 90,000 African villages being treated by nearly 
300,000 community distributors throughout APOC projects. 
The average cost per person treated, including volunteers’ 
time, is US$0.74, making CDTI highly cost-effective [9]. 
Besides, the cost per person treated as part of APOC 
(not including the value of Mectizan) is nearly 8.5 times 
cheaper than the cost per person protected, via vector 
control, under the OCP [42]. In addition, the CDTI strategy 
has empowered communities to such an extent that it is 
currently being used as a platform for integrating other, 
mainly chemotherapeutic community-based interventions 
(such as vitamin A supplementation and albendazole for 
lymphatic ﬁ lariasis treatment). Integration with other control 
programs may help maintain high coverage levels as clinical 
symptoms of onchocerciasis subside [58]. However, in spite 
of its impressive achievements in terms of coverage, and the 
promising perspectives of combined community-directed 
interventions, APOC has to face serious challenges in terms 
of achieving its ultimate treatment goal of both long-term 
sustainability and substantial permanent impact. 
In those areas where onchocerciasis and loiasis (caused by 
the ﬁ larial nematode Loa loa) are coendemic (mainly central 
Africa), ivermectin treatment for O. volvulus in individuals with 
high L. loa microﬁ laraemia can result in severe adverse events, 
including fatal encephalopathy [59]. This has represented an 
important setback to APOC’s expansion. Geostatistical models 
are being developed to map the risk of heavy loiasis across 
Africa [60], and treatment protocols will be tested aimed to 
reduce L. loa microﬁ laraemia prior to ivermectin treatment. 
Studies aimed at evaluating the sustainability of APOC-
sponsored projects have also revealed that communities do 
not always support distributors adequately; the continued 
commitment of distributors is often maintained because 
of their involvement in other more “lucrative” activities, 
such as immunization. Lack of resources makes supervision 
difﬁ cult at the community and health facility levels, and many 
obstacles must yet be overcome to integrate CDTI successfully 
with other health activities [61]. 
These concerns raise questions as to how long APOC 
should last. When launched, it was anticipated that APOC’s 
duration would be 12 years (1995 through 2007). Since then, 
a two-year phasing-out period has been added, and donors’ 
support secured until 2010. Presently, no decisions regarding 
further extensions have been made, but, given the life cycles 
of the parasite and its vector, APOC’s activities would likely 
need to be sustained for at least 20 years to have a signiﬁ cant 
and enduring impact [42]. 
Need for Other Effective Compounds against 
O. volvulus
The increasing reliance of onchocerciasis control upon 
ivermectin alone, and the absence of a real breakthrough in 
vaccine development [62], have spurred research on other 
compounds. Moxidectin has emerged as a highly efﬁ cacious 
microﬁ laricide whose half-life in humans is longer than that 
of ivermectin [63]; it may therefore suppress adult worm 
fecundity for longer [63]. Its chemical structure is similar to 
that of ivermectin, and, in animal models, it does not seem to 
be truly macroﬁ laricidal [64]. 
Novel chemotherapeutic interventions could be based on 
the use of antibiotics against the endosymbiotic bacteria, as 
long-term depletion of Wolbachia impairs worm reproduction 
and survival [65]. Daily treatment with 100 milligrams of 
doxycycline for six weeks (or 200 milligrams daily for four 
weeks) leads to an interruption of embryogenesis that lasts for 
18 months or more [66]. However, the prolonged duration 
of treatment, the various contraindications to antibiotics, and 
the risk of inducing resistance in other pathogens make it 
difﬁ cult to incorporate these regimens in mass chemotherapy 
programs. Research on the efﬁ cacy of other antibiotics and 
the shortest course of treatment that can effectively remove 
the bacteria permanently may help overcome some of these 
obstacles [67]. Alternatively, anti-Wolbachia therapy could 
be used to treat selectively those individuals identiﬁ ed as 
microﬁ laria-positive at the end of mass ivermectin distribution 
in order to “mop up” areas where parasite elimination is 
deemed feasible. 
It is to be expected that the scaling up of all ivermectin-
reliant control programs (previous OCP countries and those 
within APOC and OEPA) will impose selection pressures 
on the parasite genome. Although no conﬁ rmed case of 
ivermectin resistance has yet been identiﬁ ed, a phenotype 
of suboptimal response to the drug has been reported in 
localities in Ghana subjected to more than nine treatments 
[68]. This phenomenon appears to be explained not by loss 
of microﬁ laricidal efﬁ cacy, but by adult females resuming 
reproductive activity earlier than expected. Evidence of 
selection operating upon polymorphic loci (associated 
with ivermectin resistance in veterinary nematodes) has 
been documented by genetic analysis of worms obtained 
from patients who had received six or more annual doses 
in comparison to those who were ivermectin-naïve [69]. 
However, the deﬁ nitive studies linking response phenotype 
to parasite genotype with increasing treatment doses have yet 
to be conducted. Mathematical models can help understand 
parasite population biology processes that inﬂ uence rates 
of infection recrudescence [70,71] and the spread of alleles 
favored by ivermectin-induced selection. 
Modeling for Onchocerciasis Control
Onchocerciasis is one of the best examples in the history of 
parasitic control in which intervention strategies have been 
informed at all stages by computer simulation models. In 
particular, ONCHOSIM, a computer program for modeling 
onchocerciasis transmission and control, was developed 
under the sponsorship of OCP for West African savannah 
settings [72]. Other models pertain to transmission and 
control in forest areas and Latin American foci [73]. The 
key question of how long antiﬁ larial treatment should be 
administered depends on the anticipated goals and the 
particular epidemiology of speciﬁ c foci. If the objective is 
elimination of onchocerciasis as a public health problem, 
annual ivermectin administration in APOC countries will 
constitute a successful strategy once the levels of infection in 
the community are reduced below ﬁ ve to ten microﬁ lariae 
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per skin snip, but this is unlikely to interrupt transmission 
of O. volvulus in Africa [74]. Factors such as the intensity 
and seasonality of transmission, the Onchocerca–Simulium 
combination(s) present, the parasite distribution among 
hosts, the density-dependent processes operating upon the 
parasite’s life cycle, and the interaction of all these with 
control interventions and their coverage will determine 
the stability of the host–parasite system and our ability (or 
inability) to push O. volvulus below possible transmission 
breakpoints [70,71,73]. 
Conclusion
Neglect manifests itself in many guises. Financial and 
political commitment are required not only to support the 
control programs but also to fund the research necessary 
to provide the tools to enable parasite elimination. The 
spectacular success of the OCP has pushed onchocerciasis 
down to the bottom of the health research agenda at a time 
when consolidating its achievements and demonstrating 
long-term success in APOC and OEPA are of utmost 
importance. Priority should be given to the development 
of tools for improved diagnosis (detection of skin 
microﬁ lariae will lose sensitivity as control progresses, and 
parasite antigen tests have proved elusive), efﬁ cacious 
killing of adult worms, early detection of potential loss of 
drug efﬁ cacy and associated parasite genetic changes, and 
better understanding of the impact of chemotherapeutic 
interventions upon the population biology of O. volvulus. At 
present, the prospect of indeﬁ nite ivermectin distribution 
risks the development of anthelmintic resistance and tempts 
public and donor fatigue. 
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